Author

Sanjana U. Miskin

Observed name: Sanjana Miskin

OpenAlex ID: A5115022880

First Results from the Dose Escalation Part of the Phase 1 Study of KTX1001, an Oral, First-in-Class, Potent Inhibitor of MMSET/NSD2 for Relapsed/Refractory Multiple Myeloma (RRMM)

2024 · Pierre Bories, Cristina Gasparetto, et al. · Blood · 1

NSD2 inhibition as a therapeutic approach for treatment-induced neuroendocrine prostate cancer.

2025 · Lan Xu, J Erin Flynt, et al. · Journal of Clinical Oncology

Works count: 2

Citation count: 1

H-index: 1

I10-index: